PATENT CLAIM ANALYSIS

Application Number: 16420900
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "019300"]

Abstract:
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.

Claim (Index 28):
The method of  claim 27  wherein the leucine aminopeptidase inhibitor is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine.

Metadata:
- Claim Count in Document: 83.0
- Percentile: 100.0
- Lexical Diversity: 2.90244
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13371076', '15158679', '15158712', '16298504', '14750877']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8442280591865685
- 35 USC 102 Novelty (BERT): 0.6655404831705626
- Combined Prediction Score: 0.826359301584968
- Mean Citation Score: 627.35828
- Max Citation Score: 641.1799
- Similarity Product: 633.6042374551891

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test